157 related articles for article (PubMed ID: 34078054)
21. Gene expression in triple-negative breast cancer in relation to survival.
Wang S; Beeghly-Fadiel A; Cai Q; Cai H; Guo X; Shi L; Wu J; Ye F; Qiu Q; Zheng Y; Zheng W; Bao PP; Shu XO
Breast Cancer Res Treat; 2018 Aug; 171(1):199-207. PubMed ID: 29748761
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of CCNE1 confers a poorer prognosis in triple-negative breast cancer identified by bioinformatic analysis.
Yuan Q; Zheng L; Liao Y; Wu G
World J Surg Oncol; 2021 Mar; 19(1):86. PubMed ID: 33757543
[TBL] [Abstract][Full Text] [Related]
23. Screening Hub Genes as Prognostic Biomarkers of Hepatocellular Carcinoma by Bioinformatics Analysis.
Zhou Z; Li Y; Hao H; Wang Y; Zhou Z; Wang Z; Chu X
Cell Transplant; 2019 Dec; 28(1_suppl):76S-86S. PubMed ID: 31822116
[TBL] [Abstract][Full Text] [Related]
24. Identification of hub genes in triple-negative breast cancer by integrated bioinformatics analysis.
Wei LM; Li XY; Wang ZM; Wang YK; Yao G; Fan JH; Wang XS
Gland Surg; 2021 Feb; 10(2):799-806. PubMed ID: 33708561
[TBL] [Abstract][Full Text] [Related]
25.
Uzelac B; Krivokuca A; Susnjar S; Milovanovic Z; Supic G
Genet Test Mol Biomarkers; 2021 Mar; 25(3):227-235. PubMed ID: 33734898
[No Abstract] [Full Text] [Related]
26. Identification of NUF2 and FAM83D as potential biomarkers in triple-negative breast cancer.
Zhai X; Yang Z; Liu X; Dong Z; Zhou D
PeerJ; 2020; 8():e9975. PubMed ID: 33005492
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of BUB1B, CCNA2, CDC20, and CDK1 in tumor tissues predicts poor survival in pancreatic ductal adenocarcinoma.
Dong S; Huang F; Zhang H; Chen Q
Biosci Rep; 2019 Feb; 39(2):. PubMed ID: 30765611
[TBL] [Abstract][Full Text] [Related]
28. BUBs Are New Biomarkers of Promoting Tumorigenesis and Affecting Prognosis in Breast Cancer.
Wang S; Liu X; Yang M; Yuan D; Ye K; Qu X; Wang X
Dis Markers; 2022; 2022():2760432. PubMed ID: 35493295
[TBL] [Abstract][Full Text] [Related]
29. Identification of key molecular markers in epithelial ovarian cancer by integrated bioinformatics analysis.
Qin W; Yuan Q; Liu Y; Zeng Y; Ke D; Dai X; Shuai Y; Hu J; Shi H
Taiwan J Obstet Gynecol; 2021 Nov; 60(6):983-994. PubMed ID: 34794761
[TBL] [Abstract][Full Text] [Related]
30. Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.
Wei Z; Sijia F; Rui T; Yang L; Jianjun H; Bin W; Jing X
Ann Diagn Pathol; 2021 Dec; 55():151834. PubMed ID: 34610510
[TBL] [Abstract][Full Text] [Related]
31. Identification of Key Prognostic Genes of Triple Negative Breast Cancer by LASSO-Based Machine Learning and Bioinformatics Analysis.
Chen DL; Cai JH; Wang CCN
Genes (Basel); 2022 May; 13(5):. PubMed ID: 35627287
[TBL] [Abstract][Full Text] [Related]
32. Prognostic Significance of CCNB2 Expression in Triple-Negative Breast Cancer.
Cao J; Sun S; Min R; Li R; Fan X; Han Y; Feng Z; Li N
Cancer Manag Res; 2021; 13():9477-9487. PubMed ID: 35002325
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of differentially expressed genes associated with PLK1 in bladder cancer.
Zhang Z; Zhang G; Gao Z; Li S; Li Z; Bi J; Liu X; Li Z; Kong C
BMC Cancer; 2017 Dec; 17(1):861. PubMed ID: 29246203
[TBL] [Abstract][Full Text] [Related]
34. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
35. TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer.
Maire V; Baldeyron C; Richardson M; Tesson B; Vincent-Salomon A; Gravier E; Marty-Prouvost B; De Koning L; Rigaill G; Dumont A; Gentien D; Barillot E; Roman-Roman S; Depil S; Cruzalegui F; Pierré A; Tucker GC; Dubois T
PLoS One; 2013; 8(5):e63712. PubMed ID: 23700430
[TBL] [Abstract][Full Text] [Related]
36. Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer.
Bissanum R; Kamolphiwong R; Navakanitworakul R; Kanokwiroon K
Transl Cancer Res; 2022 Sep; 11(9):3039-3049. PubMed ID: 36237261
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
38. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
39. Identification of a Group of Therapeutic Targets and Prognostic Biomarker for Triple Negative Breast Cancer.
Li Y; Yang S; Qi L; Li Y; Wang X
Adv Ther; 2024 Apr; 41(4):1621-1636. PubMed ID: 38421558
[TBL] [Abstract][Full Text] [Related]
40. Bioinformatics Analysis of Candidate Genes and Pathways Related to Hepatocellular Carcinoma in China: A Study Based on Public Databases.
Zhang P; Feng J; Wu X; Chu W; Zhang Y; Li P
Pathol Oncol Res; 2021; 27():588532. PubMed ID: 34257537
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
